MicroLC-HRMS selective quantification of a biotherapeutic fusion protein in plasma and cerebrospinal fluid of patients with Lafora disease using a linker-containing signature peptide
Journal of Pharmaceutical and Biomedical Analysis · 2026-10 · 279 · 117574
DOI: 10.1016/j.jpba.2026.117574 ↗Kurz gefasst
Validierungsstudie in der Zeitschrift Journal of Pharmaceutical and Biomedical Analysis, 2026-10. Verfasst von Erika Esposito und 12 weiteren Autor:innen. Beteiligte Einrichtung: IRCCS Istituto delle Scienze Neurologiche di Bologna, Laboratorio di Proteomica Metabolomica e Chimica Bioanalitica, Bologna, Italy. Hauptthemen laut MEDLINE: Peptides, Recombinant Fusion Proteins. Die Arbeit nennt 24 Literaturangaben. Gefördert von: European Commission, Ministry of Health.
Abstract (Originalsprache)
Although mass spectrometry-based approaches are increasingly used for protein biotherapeutic bioanalysis, validated workflows remain limited for fusion proteins across multiple clinical matrices, including cerebrospinal fluid (CSF). We developed a microflow liquid chromatography-high-resolution mass spectrometry (HRMS) bottom-up proteomics assay for VAL-1221, an investigational fusion protein (cell-penetrating antibody Fab linked to recombinant human acid α-glucosidase). HRMS data were acquired in data-dependent acquisition (DDA) mode to support untargeted characterization of the digest and select a linker-containing signature peptide. Quantification was performed by extracted-ion chromatogram (XIC) integration of a quantifier signal, with confirmation by a qualifier signal. The method was validated in plasma and cerebrospinal fluid, including assessment of selectivity, linearity, precision and accuracy, matrix effects, recovery, and stability. The assay was linear over 68-1700 nM in plasma and 6.8-1700 nM in CSF (coefficients of determination ≥ 0.998), with lower limits of quantification of 55.8 and 5.2 nM, respectively, and precision and accuracy were within 15%. The matrix factor was 80.5% in plasma and 102.4% in cerebrospinal fluid. Applied to compassionate-use samples from five patients with Lafora disease receiving intravenous VAL-1221 (20 mg/kg every other week), VAL-1221 was detected in plasma up to 4 h post-infusion, whereas cerebrospinal fluid concentrations were below the method detection limit under the tested regimen. Overall, this workflow provides a validated, sequence-specific approach for exposure and biodistribution assessment of fusion-protein biotherapeutics in human matrices.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- IRCCS Istituto delle Scienze Neurologiche di Bologna, Laboratorio di Proteomica Metabolomica e Chimica Bioanalitica, Bologna, Italy.
- IRCCS Istituto delle Scienze Neurologiche di Bologna, Full Member of the European Reference Network for Rare and Complex Epilepsies (EpiCARE), Bologna, Italy. Electronic address: lorenzo.muccioli@ausl.bologna.it.
- Department of Biomedical and Neuromotor Sciences, University of Bologna, Bologna, Italy.
- IRCCS Istituto delle Scienze Neurologiche di Bologna, Full Member of the European Reference Network for Rare and Complex Epilepsies (EpiCARE), Bologna, Italy.
- IRCCS Istituto delle Scienze Neurologiche di Bologna, Full Member of the European Reference Network for Rare and Complex Epilepsies (EpiCARE), Bologna, Italy; Department of Biomedical and Neuromotor Sciences, University…
- IRCCS Istituto delle Scienze Neurologiche di Bologna, Laboratorio di Proteomica Metabolomica e Chimica Bioanalitica, Bologna, Italy; Department of Chemistry "G. Ciamician", University of Bologna, Italy.
Förderung
- European Commission
- Ministry of Health
Zitieren
APA
Esposito, E., Caravelli, A., Muccioli, L., Cancellerini, C., Tappatà, M., Pizzi, E., Minardi, R., DEFEAT-LD Study Group, Carelli, V., Vignatelli, L., Michelucci, R., Bisulli, F., & Fiori, J. (2026). MicroLC-HRMS selective quantification of a biotherapeutic fusion protein in plasma and cerebrospinal fluid of patients with Lafora disease using a linker-containing signature peptide. Journal of Pharmaceutical and Biomedical Analysis, 279, 117574. https://doi.org/10.1016/j.jpba.2026.117574
Vancouver
Esposito E, Caravelli A, Muccioli L, Cancellerini C, Tappatà M, Pizzi E, et al. MicroLC-HRMS selective quantification of a biotherapeutic fusion protein in plasma and cerebrospinal fluid of patients with Lafora disease using a linker-containing signature peptide. Journal of Pharmaceutical and Biomedical Analysis. 2026;279:117574. doi:10.1016/j.jpba.2026.117574
BibTeX
@article{Esposito2026,
author = {Esposito, Erika and Caravelli, Alice and Muccioli, Lorenzo and Cancellerini, Chiara and Tappatà, Maria and Pizzi, Eleonora and Minardi, Raffaella and DEFEAT-LD Study Group, DEFEAT-LD Study Group and Carelli, Valerio and Vignatelli, Luca and Michelucci, Roberto and Bisulli, Francesca and Fiori, Jessica},
title = {MicroLC-HRMS selective quantification of a biotherapeutic fusion protein in plasma and cerebrospinal fluid of patients with Lafora disease using a linker-containing signature peptide},
journal = {Journal of Pharmaceutical and Biomedical Analysis},
year = {2026},
volume = {279},
pages = {117574},
doi = {10.1016/j.jpba.2026.117574}
}
EUVIMED